The Oral Peptide Delivery Race: Approvals, Formulation Science, and the Investment Wave Reshaping Drug Development in 2026

Key takeaways

• Johnson & Johnson's icotrokinra (Icotyde), an oral macrocyclic peptide targeting the IL-23 receptor, received FDA approval for plaque psoriasis in March 2026 — the first approval of its class and a proof-of-concept for orally bioavailable macrocycles.
• Novo Nordisk committed up to $2.1 billion to MIT spinout Vivtex Corporation in February 2026 to develop next-generation oral formulations for peptide and protein therapeutics in obesity and diabetes.
• Pinnacle Medicines closed an oversubscribed $89 million Series B in March 2026 to advance its AI- and physics-based oral peptide platform into clinical trials in immunology and cardiometabolic disease.
• Syneron Bio raised $150 million in a Series B in April 2026 for its macrocyclic peptide discovery platform, backed by an existing AstraZeneca partnership worth up to $3.4 billion in potential milestones.
• A March 2026 peer-reviewed review in Frontiers in Drug Delivery characterises the core biophysical barriers that still limit oral peptide bioavailability, providing a useful reference for researchers evaluating formulation strategies.

Why 2026 has become a pivot year

For most of the past three decades, peptide therapeutics have been delivered by injection. The reason is not therapeutic efficacy — peptides are highly selective and potent across a range of targets — but rather the biophysical properties of the molecule class itself. A March 2026 review published in Frontiers in Drug Delivery describes the fundamental constraints: peptides tend to exhibit high polarity, large molecular size, charge, and proteolytic instability, properties that collectively produce low and often insufficient systemic bioavailability following oral administration.

These barriers have been understood for decades. What has changed in 2026 is the convergence of three forces: computational design tools capable of engineering peptides with improved membrane permeability; formulation science platforms that can systematically screen excipient combinations at scale; and a capital environment willing to fund the resulting programmes into the clinic.

The commercial validation arrived in March 2026, when icotrokinra (Icotyde, JNJ-77242113) received FDA approval as an oral macrocyclic peptide for plaque psoriasis. The compound blocks the IL-23 receptor and was developed by Johnson & Johnson. Its approval is significant for formulation researchers because it demonstrates that a macrocyclic peptide — a structural class described as bridging small molecules and biologics — can achieve sufficient gastrointestinal absorption for a clinically meaningful systemic effect.

Earlier, in January 2026, oral semaglutide (Wegovy in pill form) launched in the United States, adding a second approved oral peptide product to the market within weeks. Novo Nordisk's oral semaglutide uses salcaprozate sodium (SNAC) as an absorption-enhancing excipient, a formulation approach that has now set a widely referenced benchmark against which newer platforms are measured.

The Vivtex–Novo Nordisk partnership: what the deal structure signals

On 25 February 2026, Novo Nordisk and Vivtex Corporation announced a partnership valued at up to $2.1 billion in upfront consideration, research funding, and milestone payments, plus tiered royalties on future product sales. Vivtex, a spinout of MIT founded in 2018, will license its oral drug-delivery technologies to Novo for programmes targeting obesity, diabetes, and associated comorbidities.

According to Novo Nordisk's announcement, the partnership combines Novo's peptide and protein therapeutics expertise with Vivtex's proprietary gastrointestinal screening and formulation platform. Vivtex's technology evaluates how a pharmaceutical is absorbed by the intestine and how different combinations of known excipients can improve that process, using high-throughput experimentation and AI-enabled analytics. The platform's broader partner network already includes Astellas Pharma, Equillium, and Orbis Medicines, according to MedCity News.

The deal structure — a delivery-technology licence rather than a co-development of a specific molecule — reflects the pharmaceutical industry's growing appetite to de-risk oral bioavailability as a platform problem rather than solving it compound-by-compound. For research organisations assessing formulation suppliers and excipient sources, this framing is relevant: platform-based oral delivery approaches are attracting the largest deal values.

Financing: Pinnacle, Syneron, and the macrocycle moment

Pinnacle Medicines

Pinnacle Medicines closed an oversubscribed $89 million Series B on 26 March 2026, bringing its total funding to $134 million since its 2024 founding. The round was co-led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, and existing investor OrbiMed.

Proceeds are intended to advance lead oral peptide programmes through clinical proof of concept, with an initial focus on immunology and cardiometabolic diseases. Pinnacle's pipeline spans asthma and COPD, inflammatory bowel disease, atopic dermatitis, obesity, and cardiovascular indications, according to The Pharmaletter. The company integrates physics-based molecular simulation, AI-enabled design, and advanced peptide chemistry in its discovery platform, with the stated aim of delivering biologic-level safety and efficacy in an orally dosed medicine.

The challenge Pinnacle is attempting to solve is well-characterised in the literature. As MedCity News noted in its coverage of the raise, one of the central difficulties for pill-form peptides is that the amount of drug available to provide a therapeutic effect following oral administration is very low — a consequence of the same permeability and stability barriers described in the Frontiers review.

Syneron Bio

Peptide drug discovery company Syneron Bio closed a $150 million Series B in April 2026, led by an unnamed international life sciences fund alongside Decheng Capital, CDH VGC, a subsidiary of the Abu Dhabi Investment Authority, True Light Capital, Qiming Venture Partners, and BioTrack, as well as existing investors including AstraZeneca. The raise follows a nearly $100 million Series A/A+ closed in December 2025.

Syneron's platform, called Synova, uses artificial intelligence for macrocyclic peptide discovery. The company had previously signed a partnership with AstraZeneca in March 2025, granting the pharma company access to its platform in a deal worth $75 million in upfront and near-term milestone payments plus up to $3.4 billion in potential development and commercial milestones. Macrocyclic peptides have attracted particular attention for their capacity to address targets that neither small molecules nor conventional biologics can reach efficiently.

The formulation science underpinning the investment

The commercial momentum described above rests on a set of formulation strategies that research teams should be familiar with when evaluating suppliers and analytical methods.

According to the March 2026 Frontiers in Drug Delivery review, peptide therapeutics have emerged as a rapidly expanding drug class capable of modulating highly specific and previously inaccessible molecular targets. The review, authored by researchers including Thomas von Erlach (Vivtex Corporation), documents how high polarity, charge, molecular size, and proteolytic instability collectively undermine epithelial permeability for most peptide scaffolds.

Strategies under active investigation include: backbone cyclisation and N-methylation to reduce amide bond susceptibility to proteases; absorption enhancers such as SNAC (used in Novo's oral semaglutide) and medium-chain fatty acid derivatives; nanoparticle and lipid-based carrier systems; and receptor-mediated transcytosis. The icotrokinra approval provides a clinical precedent specifically for macrocyclisation as a bioavailability strategy — the ring structure constrains the peptide's conformation and reduces its susceptibility to degradation in the gastrointestinal lumen.

For laboratory procurement teams, the practical implication is that the analytical benchmarks used to assess oral peptide API quality are more demanding than those applied to injectable compounds. Permeability assays (Caco-2, PAMPA), in addition to standard purity measures by HPLC and mass spectrometry, are increasingly expected in Certificates of Analysis for compounds intended for oral formulation research. Lot-to-lot consistency in cyclic or modified peptide structures is particularly consequential, as small variations in ring closure or N-methylation can substantially alter permeability outcomes.

What this means for research-procurement professionals

The convergence of clinical validation, large-scale partnership deals, and oversubscribed Series rounds in 2026 indicates that oral peptide delivery will generate significant demand for specialised formulation excipients, analytical services, and modified peptide APIs over the next two to three years. Research laboratories working in this area should expect:

• Higher purity and characterisation standards from API suppliers, with an emphasis on confirming cyclisation or modification completeness via mass spectrometry.
• Excipient sourcing complexity, particularly for absorption enhancers where regulatory-grade material specifications differ from research-grade material.
• Increased supplier scrutiny, as the FDA's ongoing enforcement activity on research-use-only peptide vendors (including five warning letters issued in September 2026) creates reputational and compliance pressure across the supply chain.

The oral peptide class is no longer a theoretical aspiration. With two approved oral peptide products on the US market, at least $3 billion in new industry commitments to platform development in 2026 alone, and peer-reviewed formulation science advancing in parallel, the category now warrants the same procurement rigour that injectable peptide programmes have required for years.